N. Barnes (London, United Kingdom), E. Derom (Gent, Belgium)
Acute dose- and time-dependent effects of budesonide on airway blood flow in asthma
E. Mendes, P. Rebolledo, J. Arana, M. Campos, A. Wanner (Miami, United States Of America)
|   |
Budesonide reverses IL-13–induced airway hyper-responsiveness but has little effect on β2 agonist response in human small airways
C. Koziol-White, P. Cooper, J. Zhang, I. Dainty, R. Panettieri Jr. (Philadelphia, Radnor, United States Of America; Mölndal, Sweden)
| |
Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301
H. Pietschmann, H. Fischer, S. Tzotzos, B. Fischer, M. Zeitlinger, R. Lucas, R. Hermann, H. Mascher (Vienna, Austria; Augusta, United States Of America)
| |
ENaC-activating effect of AP301 in type II alveolar cells isolated from dog, pig and rat lungs
S. Tzotzos, B. Fischer, H. Fischer, H. Pietschmann, R. Lucas, G. Dupre, W. Shabbir, R. Lemmens-Gruber (Vienna, Austria; Augusta, United States Of America)
| |
MEMP1972A, an anti-M1 prime monoclonal antibody, reduces serum IgE in healthy and allergic rhinitis subjects
H. Scheerens, W. Putnam, Y. Zheng, Y. Wang, S. Mosesova, R. Maciuca, C. Liao, L. Wu, J. Matthews, J. Harris (San Francisco, United States Of America)
| |
IgE-induced pro-inflammatory extracellular matrix composition in airway smooth muscle cells is prevented by omalizumab
M. Roth, J. Zhong, C.T. S‘ng, M. Tamm (Basel, Switzerland)
| |
The effects of extrafine beclomethasone/formoterol on hyperinflation and airway geometry in COPD patients
S. Vinchurkar, W. Vos, C. Holsbeke, J. De Backer, G. Poli, W. De Backer (Kontich, Edegem, Belgium; Parma, Italy)
| |
Formoterol reduces asthmatic airway smooth muscle cell proliferation through p27 (Kip) which is supported by steroids
M. Roth, J. Zhong, P. Borger, C.T. S‘ng, M. Tamm (Basel, Switzerland)
| |
Synergistic effects between glycopyrronium bromide and indacaterol on a muscarinic agonist-induced contraction in airway smooth muscle
H. Kume, S. Imbe, T. Iwanaga, Y. Tohda (Osakasayama, Japan)
| |
Cyclic AMP mediates the anti-asthma properties of the lidocaine analog JMF2-1
P. Olsen, L. Coelho, J. Costa, R. Cordeiro, P. Silva, M. Martins (Rio de Janeiro, Brazil)
| |
Evidence for a non-β2-adrenoceptor (β2AR) binding site in human lung tissue for the long acting β2-agonist (LABA) vilanterol
R. Slack, V. Barrett, A. Ford, R. Knowles (Stevenage, United Kingdom)
| |
Small impact of mild and moderate renal impairment on the pharmacokinetics of inhaled NVA237
R. Sechaud, A. Drollmann, H. Hara, R. Karan, C. Boulton, L. Di Scala, A. Dmitriev, S. Villevalde, Z. Kobalava, G. Kaiser (Basel, Switzerland; Hyderabad, India; Horsham, United Kingdom; Moscow, Russian Federation)
| |
Efficient deposition and sustained lung concentrations of NVA237 after inhalation via the Breezhaler® device in man
R. Sechaud, M. Sudershan, S. Perry, H. Hara, A. Drollmann, R. Karan, L. Di Scala, S. Biswal, B. Patterson, G. Kaiser (Basel, Switzerland; Horsham, United Kingdom; Hyderabad, India)
| |
Guaifenesin suppresses MUC5AC content and secretion in human airway epithelial cell cultures: Comparison with N-acetylcysteine and ambroxol
J. Seagrave, H. Albrecht, D. Rogers, G. Solomon (Albuquerque, Parsippany, United States Of America; London, United Kingdom)
| |
Guaifenesin alters mucus rheology and improves mucociliary transport in human airway epithelial cell cultures: Comparison with N-acetylcysteine and ambroxol
J. Seagrave, H. Albrecht, D. Hill, D. Rogers, G. Solomon (Albuquerque, Parsippany, United States Of America; London, United Kingdom)
| |
The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteers
U. Lorch, H. Negi, H. Tabata, H. Wray, M. Cullberg, B. Larsson (London, United Kingdom; Osaka, Japan; Mölndal, Sweden)
| |
Combining corticosteroids and NK1R antagonists: A new drugs combination to treat allergic diseases
K. Maghni, L. Castellanos, S. Favret, M. Welman (Montreal, Canada)
| |
Advantageous toxicity profile of an inhaled GATA-3-specific DNAzyme intended for anti-inflammatory treatment of Th2-driven asthma
R. Fuhst, F. Runge, J. Buschmann, C. Praechter, J. von Erichsen, A. Turowska, H.G. Hoymann, M. Müller, G. Pohlmann, K. Sewald, C. Ziemann, G. Schlüter, H. Garn (Hanover, Barsbüttel, Marburg, Wuppertal, Germany)
| |